T

he Swiss attorney general has decided not to pursue criminal charges against Novartis in connection with $1.2 million in payments the company made last year to President Trump’s personal attorney for access to the new administration.

In explaining its decision, the federal prosecutor maintained there was “insufficient” reason to pursue bribery charges that may have violated laws governing payments to foreign public officials or any link between the payments and any official government action. The prosecutor, which had received a criminal complaint, also noted “that Swiss law does not recognize an offence of trading in influence, whether within Switzerland or internationally.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy